"Hepatic Substrate Flux Rates in Type 2 Diabetes" (IMPACT)

German Diabetes Center

Status: Active, not recruiting

Conditions: Type 2 Diabetes

Treatments: Drug: On Metformin; Drug: Off Metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT04088851

IMPACT

Details and patient eligibility

About

Investigation of the effects of redox shuttle inhibition by metformin on gluconeogenic flux rates of lactate and glycerol in humans with type 2 diabetes

Full description

Type 2 diabetes (T2D) is characterized by insulin resistance and relative insulin deficiency leading to hyperglycemia. Enhanced endogenous glucose production during fasting is a key feature of hepatic insulin resistance and a major contributor to deterioration of glycemia. Metformin reduces fasting gluconeogenesis (GNG); the underlying mechanisms are still not fully understood, but involve the inhibition of complexes of the electron transport chain and thus the redox shuttle.

The investigators have previously provided evidence for abnormal hepatic ATP synthesis and mitochondrial efficiency in T2D, but it remains unknown, how and which substrate fluxes account for excessive GNG in T2D. For this reason, this proposal aims at investigating hepatic glucose and energy fluxes in T2D with focus on gluconeogenic contribution of lactate and glycerol to hepatic mitochondrial substrate flux, mitochondrial ATP synthase flux and the activity of the redox shuttle, also after metformin intake, by using a novel combination of positional isotopomer nuclear magnetic resonance (NMR) analysis (PINTA) with multinuclei magnetic resonance spectroscopy (MRS).

Enrollment: 23 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• type 2 diabetes (duration <7 years),
• age (18-75 years)
• BMI <40 kg/m2
• HbA1c 6-15%

Exclusion criteria

• uncontrolled hyperglycaemia (>340 mg/dl)
• diabetes types other than type 2 diabetes (ADA criteria)
• thiazolidinedione use during the preceding 6 months
• clinically relevant angiopathy, restrictive or obstructive lung diseases
• other acute or chronic diseases including wounds and the use of pharmacological agents known to affect insulin sensitivity, lipid metabolism or immunological function.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

23 participants in 2 patient groups, including a placebo group

Metformin - T2D

Experimental group

Description:

Participants with type-2 diabetes will intake metformin 1 g daily for 2 weeks

Treatment:

Drug: On Metformin

No Metformin - T2D

Placebo Comparator group

Description:

Participants with type-2 diabetes will pause metformin 1 g daily for 2 weeks

Treatment:

Drug: Off Metformin